Choose Motion
Clinical results that
refuse to be ignored
Mobi-C
®
At 5 years, two-level Mobi-C patients
demonstrated SUPERIORITY in overall IDE
trial success compared to ACDF, 62.8% vs.
34.1% respectively (p<0.001).
At 5 years, two-level Mobi-C patients
demonstrated lower rates of subsequent
surgery compared to ACDF, 3.8% vs. 16.2%
respectively.
Learn more at cervicaldisc.com/clinical-results
© 2017 Zimmer Biomet Spine, Inc. All rights reserved.
All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet Spine
or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent
of Zimmer Biomet Spine. This material is intended for health care professions, Zimmer Biomet Spine employees, the Zimmer Biomet Spine sales force, and
authorized representatives. Distribution to any other recipient is prohibited. For product information, including indications, contraindications, warnings,
precautions, potential adverse effects and patient counseling information, see the package insert and www.cervicaldisc.com/aboutyourneck.
MB AD 17 Rev B 08.2017
Cervical Disc
